EyeGene Inc (185490) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.021x

Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-904.39 Million ≈ $-612.89K USD) by net assets (₩44.06 Billion ≈ $29.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

EyeGene Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of EyeGene Inc for a breakdown of total debt and financial obligations.

EyeGene Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Petratherm Ltd AU:PTR	-0.044x
Amanet Management & Systems Ltd TA:AMAN	0.066x
Micro-X Ltd AU:MX1	-0.545x
Tira Austenite Tbk JK:TIRA	0.003x
Tubos Reunidos S.A MC:TRG	0.523x
BuzzFeed Inc NASDAQ:BZFD	0.023x
Horizon Space Acquisition I Corp. Ordinary Shares NASDAQ:HSPO	0.000x
Wiscom KO:024070	0.069x

Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 185490 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩50.32 Billion ≈ $34.10 Million	₩-12.17 Billion ≈ $-8.25 Million	-0.242x	+22.45%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	₩-20.07 Billion ≈ $-13.60 Million	-0.312x	-12.09%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	₩-18.57 Billion ≈ $-12.58 Million	-0.278x	+17.49%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	₩-30.00 Billion ≈ $-20.33 Million	-0.337x	+55.40%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	₩-9.75 Billion ≈ $-6.61 Million	-0.756x	-72.94%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	₩-8.32 Billion ≈ $-5.64 Million	-0.437x	-36.42%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	₩-7.48 Billion ≈ $-5.07 Million	-0.321x	-12.64%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	₩-6.76 Billion ≈ $-4.58 Million	-0.285x	+23.06%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	₩-5.99 Billion ≈ $-4.06 Million	-0.370x	-87.96%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	₩-4.48 Billion ≈ $-3.04 Million	-0.197x	+68.29%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	₩-2.39 Billion ≈ $-1.62 Million	-0.621x	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.23 Million

₩43.14 Billion KRW

Market Cap Rank

#23786 Global

#1717 in Korea

Share Price

₩1416.00

Change (1 day)

-1.12%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00